Business Acquisition [Axis]
EGEN Inc [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Initial Horizon Credit Agreement [Member]
Contingent Consideration by Type [Axis]
Glioblastoma Multiforme Brain Cancer [Member]
Asset Class [Axis]
Goodwill [Member]
IPR&D [Member]
2018 Aspire Purchase Agreements [Member]
Finite-Lived Intangible Assets by Major Class [Axis]
Covenant Not to Compete [Member]
Legal Entity [Axis]
IPR&D Drug Technology Platforms [Member]
Ovarian Cancer [Member]
Purchase Agreement [Member]
Debt Instrument [Axis]
Initial Horizon Credit Agreement Amendment [Member]
Amendment to Horizon Credit Agreement [Member]
Horizon Technology Finance Corporation [Member]
Variable Rate [Axis]
One-Month LIBOR Exceeds 2% Plus [Member]
Equity Components [Axis]
Common Stock Outstanding [Member]
Additional Paid in Capital [Member]
Treasury Stock [Member]
Accumulated Other Comprehensive Income [Member]
Accumulated Deficit [Member]
Geographical [Axis]
New Jersey [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Range [Axis]
Minimum [Member]
Maximum [Member]
Horizon Credit Agreement [Member]
London Interbank Offered Rate (LIBOR) [Member]
Capital on DemandTM Sales Agreement [Member]
Jones Trading Institutional Services, LLC [Member]
Financial Instrument [Axis]
Corporate Debt Securities [Member]
Measurement Frequency [Axis]
Fair Value, Measurements, Recurring [Member]
Fair Value Hierarchy and NAV [Axis]
Significant Other Observable Inputs (Level 2) [Member]
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]
Significant Unobservable Inputs (Level 3) [Member]
Capital on Demand Agreement [Member]
Securities Purchase Agreement [Member]
Original Warrants [Member]
Exchange Agreements [Member]
Warrant [Member]
Underwriting Agreement [Member]
Sale of Stock [Axis]
Underwritten Offering [Member]
LPC Purchase Agreement [Member]
Lincoln Park Capital Fund, LLC [Member]
LPC Commitment Shares [Member]
January 2021 Registered Direct Offering [Member]
March 2021 Registered Direct Offering [Member]
Plan Name [Axis]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
Inducement Option Grants [Member]
Title of Individual [Axis]
Five New Employees [Member]
Award Type [Axis]
Restricted Stock [Member]
Equity Stock Awards [Member]
Scenario [Axis]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Inducement Awards [Member]
Stock Options and Restricted Stock Awards [Member]
Income Statement Location [Axis]
Research and Development Expense [Member]
General and Administrative Expense [Member]
Stock Options [Member]
Amended Asset Purchase Agreement [Member]
Related Party Transaction [Axis]
Within One Year of Achieving Milestone [Member]
10 Business Days of Achieving Milestone [Member]
EGWC, Inc [Member]
Fair Value Earnout Milestone Liability [Member]
1st Lease Amendment [Member]
First Year [Member]
Final Year [Member]
2nd Lease Amendment [Member]
Huntsville Alabama [Member]
EGEN Asset Purchase Agreement [Member]
Adjustments for New Accounting Pronouncements [Axis]
Accounting Standards Update 2016-02 [Member]
Operating Leases [Member]
Legal Entity of Counterparty, Type [Axis]
Hisun [Member]
Fair Value, Measurements, Non Recurring [Member]
In-process R&D [Member]
Cover [Abstract]
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Shell Company
Entity Common Stock, Shares Outstanding
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement of Financial Position [Abstract]
ASSETS
Current assets:
Cash and cash equivalents
Investment in debt securities - available for sale, at fair value
Receivable on sale of net operating losses
Advances and deposits on clinical programs and other current assets
Total current assets
Property and equipment (at cost, less accumulated depreciation and amortization)
Other assets:
Deferred income tax asset
In-process research and development, net
Goodwill
Operating lease right-of-use assets, net
Other intangible assets, net
Deposits and other assets
Total other assets
Total assets
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable - trade
Other accrued liabilities
Notes payable - current portion, net of deferred financing costs
Operating lease liability - current portion
Deferred revenue - current portion
Total current liabilities
Earn-out milestone liability
Notes payable - non-current portion, net of deferred financing costs
Operating lease liability - non-current portion
Deferred revenue - non-current portion
Total liabilities
Commitments and contingencies
Stockholders' equity:
Preferred Stock - $0.01 par value (100,000 shares authorized, and no shares issued or outstanding at March 31, 2021 and December 31, 2020)
Common stock - $0.01 par value (112,500,000 shares authorized; 75,019,608 and 40,701,356 shares issued at March 31, 2021 and December 31, 2020, respectively, and 75,019,274 and 40,701,022 shares outstanding at March 31, 2021 and December 31, 2020, respectively)
Additional paid-in capital
Accumulated other comprehensive gain
Accumulated deficit
Total stockholders' equity before treasury stock
Treasury stock, at cost (334 shares at March 31, 2021 and December 31, 2020)
Total stockholders' equity
Total liabilities and stockholders' equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Treasury stock, shares
Income Statement [Abstract]
Technology development and licensing revenue
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Loss from change in valuation of earn-out milestone liability
Investment income
Interest expense
Other income
Total other income (expense), net
Net loss
Net loss per common share - Basic and diluted
Weighted average shares outstanding - Basic and diluted
Statement of Comprehensive Income [Abstract]
Other comprehensive gain (loss)
Changes in:
Reclassification of realized gain on investment securities recognized in investment income, net
Unrealized gain on investment securities
Change in unrealized gain (loss), net, on available for sale securities
Net loss
Comprehensive loss
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Change in fair value of earn-out milestone liability
Fair value of warrants issued in connection with amendment to modify the GEN-1 earn-out milestone payments
Recognition of deferred revenue
Stock-based compensation costs
Deferred income tax asset
Amortization of deferred finance charges and debt discount associated with notes payable
Net changes in:
Accrued interest on investment securities
Receivable on sale of net operating losses
Advances, deposits, and other current assets
Accounts payable and accrued liabilities
Net cash (used in) operating activities:
Cash flows from investing activities:
Purchases of investment securities
Proceeds from sale and maturity of investment securities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from sale of common stock equity, net of issuance costs
Proceeds from exercise of common stock warrants
Proceeds from exercise of options to purchase common stock
Net cash provided by financing activities
Increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Interest paid
Cash paid for amounts included in measurement of lease liabilities:
Operating cash flows from lease payments
Stock issued in lieu of cash bonuses
Realized and unrealized gains (losses), net, on investment securities
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Sale of equity through equity financing facilities net of fees
Sale of equity through equity financing facilities net of fees, shares
Shares issued upon exercise of common stock warrants, net of fees
Shares issued upon exercise of common stock warrants, net of fees, shares
Shares issued upon exercise of options to purchase common stock
Shares issued upon exercise of options to purchase common stock, shares
Realized and unrealized gains and losses, net, on investment securities
Stock-based compensation expense
Issuance of restricted stock
Issuance of restricted stock, shares
Balance
Balance, shares
Accounting Policies [Abstract]
Business Description
Basis of Presentation
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Condition and Business Plan
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements
Earnings Per Share [Abstract]
Net Loss Per Common Share
Investments, Debt and Equity Securities [Abstract]
Investments in Debt Securities Available for Sale
Fair Value Disclosures [Abstract]
Fair Value Measurements
Intangible Assets, Net (Including Goodwill) [Abstract]
Intangible Assets
Payables and Accruals [Abstract]
Accrued Liabilities
Debt Disclosure [Abstract]
Note Payable
Equity [Abstract]
Stockholders' Equity
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation
Hercules Warrant [Member]
Earn-out Milestone Liability
Warrants and Rights Note Disclosure [Abstract]
Warrants
Leases [Abstract]
Leases
Exercise Price Three [Member]
Technology Development and Licensing Agreements
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Subsequent Events [Abstract]
Subsequent Events
Schedule of Cost, Fair Value and Maturities of Short Term Investments
Summary of Investment Securities Gross Unrealized Gains (Losses)
Summary of Net Realized Losses on Sales of Available for Sale Securities and Investment Income Interest and Dividends
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis
Schedule of Future Amortization Amounts During the Remaining Life
Schedule of Fair Value of Assets Acquired
Schedule of Accrued Liabilities
Schedule of Future Principle Payments, Net of Unamortized Debt Discounts
Summary of Stock Option Awards and Restricted Stock Grants
Schedule of Assumptions Used to Determine Fair Value of Options Granted
Schedule of Changes in Earn-out Milestone Liability
Schedule of Risk Adjustment Assessment
Summary of Warrant Activity
Schedule of Lease Payments and Maturity of Operating Lease Liabilities
Statistical Measurement [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Series [Axis]
Cumulated net losses
Cash and cash equivalents, short-term investments and receivable on sale of net operating losses
Net proceeds from sale of net operating losses
Proceeds from new capital
Debt instrument, interest rate
Repayment of loans
Debt instrument face amount
Debt instrument related end term charges
Proceeds from warrant exercises
Proceeds from sale of equity
Number of shares of common stock issuable upon exercise of warrants and equity awards
Warrants exercise price
Number of shares of common stock issued in calculation basic loss per share
Short-term investments - Fair Value
Short-term investments - Cost
Short-term investment maturities - Within 3 months, cost
Short-term investment maturities - Between 3-12 months, cost
Total, cost
Short-term investment maturities - Within 3 months, fair value
Short-term investment maturities - Between 3-12 months, fair value
Total, fair value
Investments in debt securities with unrealized gains, Less than 12 months , Fair Value
Investment securities - available for sale, Fair Value
Investments in debt securities with unrealized gains, Less than 12 months, Unrealized Holding Gains (Losses)
Unrealized Holding Gains (Losses)
Interest and dividends accrued and paid
Realized gains
Investment income net
Investment securities, available for sale
Indefinite lived intangible assets
Finite-lived intangible assets acquired
Asset impairment charges
Non-cash charge
Finite-lived intangible asset, useful life
Amortization expense
Finite-lived intangible assets, net
Finite-lived intangible assets, accumulated amortization
Goodwill, acquisition
2021
2022 and thereafter
Total
Intangible assets, beginning balance
Amortization
Intangible assets, ending balance
Amounts due to contract research organizations and other contractual agreements
Accrued payroll and related benefits
Accrued professional fees
Other
Total
Counterparty Name [Axis]
Long-term Debt, Type [Axis]
Line of credit facility, maximum borrowing capacity
Proceeds from lines of credit, total
Debt instrument interest rate
Debt instrument, interest rate terms
Debt instrument, end term fee
Debt instrument, restrictive covenants
Financing fees and expenses
Loan origination fees
Debt instrument, unamortized discount
End of term charge percentage
Debt financing fees
Warrants exercise per share
Warrants exercisable
Fair value of warrants
Warrants cancelled
Warrants outstanding
Payment of debt extinguishment
New warrants fair value
End of term fees
Interest expense, debt, total
Amortization of debt issuance costs
2022
2023
2024 and thereafter
Subtotal of future principal payments
Unamortized debt premium, net
Total
Shelf registration statement amount
Aggregate offering price
Stock issued during period, shares, new issues
Proceeds from issuance of common stock
Shares issued, price per share
Number of warrants to purchase common stock
Warrants term
Proceeds from issuance of warrants
Shares purchased, price per share
Underwriting discount price per share
Percentage of underwriting discount on public offering price
Placement agent fee description
Equity awards, number of stock authorized
Number of equity awards available for future issuance
Stock options, strike price description
Number of shares issued
Weighted average exercise price, options granted
Option vested period
Number of shares reserved for future issuance
Compensation cost
Unrecognized compensation cost related to non-vested stock based compensation
Stock based compensation cost expected to be recognized, weighted average period
Number Outstanding, Outstanding, Beginning balance
Number Outstanding, Options granted
Number Outstanding, Options exercised or vested and issued
Number Outstanding, Options canceled or expired
Number Outstanding, Outstanding, Ending balance
Number Outstanding, Exercisable, Ending balance
Weighted Average Exercise Price, Outstanding, Beginning balance
Weighted Average Exercise Price, Options granted
Weighted Average Exercise Price, Options exercised or vested and issued
Weighted Average Exercise Price, Options canceled or expired
Weighted Average Exercise Price, Outstanding, Ending balance
Weighted Average Exercise Price, Exercisable, Ending balance
Weighted Average Remaining Contractual Term (years), Outstanding, Ending balance
Weighted Average Remaining Contractual Term (years), Exercisable, Ending balance
Aggregate Intrinsic Value, Outstanding, Ending balance
Aggregate Intrinsic Value, Exercisable, Ending balance
Number Outstanding, Non-vested stock awards, Outstanding, Beginning balance
Number Outstanding, Non-vested stock awards, Granted
Number Outstanding, Non-vested stock awards, exercised or vested and issued
Number Outstanding, Non-vested stock awards, Forfeited
Number Outstanding, Non-vested stock awards, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Beginning balance
Weighted Average Grant Date Fair Value, Non-vested stock awards, Granted
Weighted Average Grant Date Fair Value, Non-vested stock awards, exercised or vested and issued
Weighted Average Grant Date Fair Value, Non-vested stock awards, Forfeited
Weighted Average Grant Date Fair Value, Non-vested stock awards, Outstanding, Ending balance
Aggregate Intrinsic Value, Non-vested stock awards, Outstanding, Ending balance
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Risk-free interest rate
Expected volatility, minimum
Expected volatility, maximum
Expected volatility
Expected life (in years)
Expected dividend yield
Earnout milestone liability
Fair value of acquisition consideration
Earn-out payment options, description
Non-cash charge on earnour milestone liability
Earn-out liabilities, beginning balance
Non-cash gain loss from the adjustment for the change in fair value
Earn-out liabilities, ending balance
Risk-adjustment Assessment of achieving each Milestone
Discount Rate
Estimated Time to Achieve
Number of Warrants Issued, Warrants outstanding, Beginning balance
Number of Warrants Issued, Warrants exercised
Number of Warrants Issued, Warrants outstanding, Ending balance
Weighted Average Exercise Price, Warrants outstanding, Beginning balance
Weighted Average Exercise Price, Warrants exercised
Weighted Average Exercise Price, Warrants outstanding, Ending balance
Aggregate intrinsic value of outstanding warrants
Weighted average remaining contractual terms (years)
Accounting Standards Update [Axis]
Area of land
Lease expiration date
Lease, term of contract
Lease, renewal term
Lease, option to extend
Lease, rent payment
Lease description
ROU asset
Operating lease liabilities
Other liabilities
Increased ROU asset
Operating lease costs
Operating lease expense paid
Remainder of 2021
2022
2023
2024 and thereafter
Subtotal future lease payments
Less imputed interest
Total lease liabilities
Weighted average remaining life
Weighted average discount rate
Non-refundable research and development fee
Deferred revenue
Deferred revenue amortization period
Upfront Payment, being recognized
Payment of legal fees
Payments for legal settlements
Sale of stock, during period
Gross proceeds from sales of stock
Amendment to Horizon Credit Agreement [Member]
Amortization of deferred finance charges and debt discount associated with note payable.
2018 Aspire Purchase Agreements [Member]
Warrants cancelled.
Information pertaining to the business acquisition of EGEN, Inc.
The disclosure related to earn-out milestone liabilities.
End of term charge percentage.
End of term fees.
Fair value of warrants issued in connection with amendment to modify GEN-1 earn-out milestone payments.
Gain (loss) from change in valuation of earn-out milestone liability.
Glioblastoma Multiforme Brain Cancer [Member]
Horizon Technology Finance Corporation [Member]
IPR&D Drug Technology Platforms [Member]
IPR&D [Member]
Initial Horizon Credit Agreement Amendment [Member]
Initial Horizon Credit Agreement [Member]
The entire disclosure for a contractual arrangement, in which the Company gave another party an exclusive license.
Non-cash charge.
Number of shares of common stock issued in calculation basic loss per share.
One-Month LIBOR Exceeds 2% Plus [Member].
Ovarian Cancer [Member]
Debt instrument related end term charges.
Purchase Agreement [Member]
Realized and unrealized (gains) and losses, net, on investment in debt securities.
The disclosure of transactions regarding the changes in earn-out liabilities during the period.
Warrants [Text Block]
Receivable on sale of net operating losses.
Increase (Decrease) in receivable on sale of net operating losses.
Shares issued upon exercise of common stock warrants, net of fees.
Shares issued upon exercise of common stock warrants, net of fees, shares.
SummaryOfStockOptionAndRestrictedStockAwardsTableTextBlock
ScheduleOfRiskadjustmentAssessmentTableTextBlock
LongTermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereAfter
New Jersey [Member]
Horizon Credit Agreement [Member]
Capital on DemandTM Sales Agreement [Member]
Jones Trading Institutional Services, LLC [Member]
LPC Purchase Agreement [Member]
Lincoln Park Capital Fund, LLC [Member]
Net proceeds from sale of net operating losses.
Represents the total number of Shares of common stock issuable upon exercise of warrants and equity awards.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
The current amount of amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three months.
Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next rolling three to twelve months.
Debt securities available for sale continuous unrealized gain position less than 12 months.
DebtSecuritiesAvailableforsaleContinuousUnrealizedGainPositionLessThan12MonthsAccumulatedGain
Amount of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position.
Capital on Demand Agreement [Member]
Securities Purchase Agreement [Member]
Original Warrants [Member]
Exchange Agreements [Member]
Underwriting Agreement [Member]
Underwritten Offering [Member]
Regular Purchase Share Limit [Member].
Exchange Cap of Common Stock [Member].
LPC Commitment Shares [Member].
2019 Aspire Purchase Agreements [Member]
2018 Aspire Purchase Agreements [Member]
Shelf Registration statement.
Aggregate offering price.
Underwriting discount price per share.
Percentage of underwriting discount on public offering price.
Placement agent fee description.
January 2021 Registered Direct Offering [Member]
March 2021 Registered Direct Offering [Member]
2018 Stock Incentive Plan [Member]
2007 Stock Incentive Plan [Member]
Inducement Option Grants [Member]
Five New Employees [Member]
Equity Stock Awards [Member]
Granted Under 2018 Plan and 2007 Plan [Member]
2018 Plan [Member]
Inducement Awards [Member]
Stock Options and Restricted Stock Awards [Member]
2019 Bonus Program [Member]
Stock options, strike price description.
Stock Options [Member]
Amended Asset Purchase Agreement [Member]
Within One Year of Achieving Milestone [Member]
10 Business Days of Achieving Milestone [Member]
EGWU, Inc [Member]
Fair Value Earnout Milestone Liability [Member]
Amended Asset Purchase Agreement Option Payment 1 [Member]
Amended Asset Purchase Agreement Option Payment 2 [Member]
Earnout milestone liability.
The amount of gain (loss) from the change in the fair value of earn-out milestone liability.
Earn-out liabilities, beginning balance.
EGWC, Inc [Member]
Earn-out payment options, description.
Non-cash charge on earnour milestone liability.
Estimated time to achieve milestone liability.
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
Share based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average exercise price.
Sharebased compensation arrangement by sharebased payment award non options outstanding intrinsic value.
Weighted average remaining contractual term for non-option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
1st Lease Amendment [Member]
First Year [Member]
Final Year [Member]
2nd Lease Amendment [Member]
Huntsville Alabama [Member]
EGEN Asset Purchase Agreement [Member]
Operating Leases [Member]
Lessee, operating lease, liability, to be paid, year four and there after.
Hisun [Member]
The amortization period for deferred revenue.
Upfront Payment, being recognized.
Risk-adjustment Assessment of achieving each Milestone.
Discount Rate on milestone liabilities.
Cash and cash equivalents, short-term investments and receivable on sale of net operating losses.
Inprocess R and D [Member]
Finite-lived intangible asset, expected amortization, year two, and after.
Assets, Current
Assets
Liabilities, Current
Liabilities
Stockholders' Equity before Treasury Stock
Treasury Stock, Value
Stockholders' Equity Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Nonoperating Income (Expense)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax
OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax
Comprehensive Income (Loss), Net of Tax, Attributable to Parent
February 14, 2017 Public Offering [Member]
Contract with Customer, Liability, Revenue Recognized
Deferred Income Tax Expense (Benefit)
Increase (Decrease) in Accrued Investment Income Receivable
IncreaseDecreaseInReceivableOnSaleOfNetOperatingLosses
Increase (Decrease) in Prepaid Expense and Other Assets
Net Cash Provided by (Used in) Operating Activities
Payments to Acquire Debt Securities, Available-for-sale
Payments to Acquire Property, Plant, and Equipment
Net Cash Provided by (Used in) Investing Activities
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Shares, Outstanding
Cost
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value
Unrealized gains (losses)
Amortization of Intangible Assets
Long-term Debt, Gross
Long-term Debt
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding
Note To Financial Statement Details Textual
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
clsn_AmountOfTimeAfterEffectiveDateOfLicenseAgreementForRegistrationRightsToTakePlace
clsn_NumberOfTrademarkProtectionApplicationPendingForThermoDox
Lessee, Operating Lease, Liability, to be Paid, Year Two
Lessee, Operating Lease, Liability, to be Paid, Year Three
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThreeAndThereAfter
Lessee, Operating Lease, Liability, to be Paid
Lessee, Operating Lease, Liability, Undiscounted Excess Amount